Jonas Bergh wins first ESMO Breast Cancer Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Society for Medical Oncology announced Jonas Bergh from the Karolinska Institutet in Stockholm will receive the newly established 2019 ESMO Breast Cancer Award in connection with the inaugural ESMO Breast Cancer Congress.

The ESMO Breast Cancer Award acknowledges experts who have devoted a major part of their career and made a special contribution to the discovery and development of education, research and clinical practice in the field of breast cancer.

Bergh is Cancer Theme Prefect and Director of Strategic Research Programme in Cancer at the Karolinska Institutet in Stockholm, where he is also member of the Nobel Assembly and holds the Mimi Althainz’ Professorship in Oncology.

Bergh is also Senior Consultant in Oncology at the Karolinska University Hospital, acting chair of the Scientific Council in Oncology/Haematology for the European Medicines Agency, Visiting Professor of Breast Cancer Research at Oxford University, and a fellow of the Royal College of Physicians in London, UK.

Bergh’s research is mainly focused on breast cancer biology, including alteration of characteristics during progression and tailored breast cancer treatments. He is co-chair of the Early Breast Cancer Trialists’ Collaborative Group, whose publications have had a global impact on primary breast cancer treatment, and was Chair of the Swedish Breast Cancer Group between 1995 and 2016.

Table of Contents

YOU MAY BE INTERESTED IN

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.

Login